Optimizerx Stock News

- COVID-19 Consumer Health Communications Campaign won silver in the Mobile Digital Health Resources: Text Messaging category - TelaRep Interactive EHR Communication received a merit award in the Connected Digital Health: Clinical Decision Support Tools category

OptimizeRx Co. (NASDAQ:OPRX) shares gapped down prior to trading on Monday after an insider sold shares in the company. The stock had previously closed at $62.23, but opened at $57.75. OptimizeRx shares last traded at $56.36, with a volume of 1,361 shares traded. Specifically, CFO Douglas P. Baker sold 2,000 shares of the firms stock []

ROCHESTER, Mich., Nov. 22, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the Company) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy today announced that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Zacks Investment Research cut shares of OptimizeRx (NASDAQ:OPRX) from a hold rating to a strong sell rating in a report released on Friday, Zacks.com reports. According to Zacks, OptimizeRx Corporation provides consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. It offers pharmaceutical and healthcare companies effective []

OptimizeRx Co. (NASDAQ:OPRX) insider Stephen L. Silvestro sold 13,241 shares of the companys stock in a transaction dated Wednesday, November 17th. The shares were sold at an average price of $73.98, for a total transaction of $979,569.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. OptimizeRx []

OptimizeRx Co. (NASDAQ:OPRX) Director Patrick D. Spangler sold 6,252 shares of the companys stock in a transaction dated Thursday, November 11th. The stock was sold at an average price of $84.38, for a total transaction of $527,543.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. OPRX []

Event to be held December 9, 2021, 1:00-4:30 PM ET Event to be held December 9, 2021, 1:00-4:30 PM ET

OptimizeRx Co. (NASDAQ:OPRX) Director Patrick D. Spangler sold 6,252 shares of OptimizeRx stock in a transaction dated Thursday, November 11th. The shares were sold at an average price of $84.38, for a total value of $527,543.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the []

OptimizeRx Co. (NASDAQ:OPRX) has earned an average recommendation of Buy from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued []

OptimizeRx (NASDAQ:OPRX) had its price objective lifted by Royal Bank of Canada from $67.00 to $100.00 in a research report report published on Wednesday morning, Analyst Price Targets reports. Royal Bank of Canada currently has an outperform rating on the stock. Several other research analysts have also weighed in on OPRX. Zacks Investment Research raised []

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -30.77% and 8.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx's (OPRX) CEO William Febbo on Q3 2021 Results - Earnings Call Transcript

The shares of OptimizeRx Corporation (NASDAQ: OPRX) have received a price target of $102 from B. Riley. These are the details.

Here's how OptimizeRx gets in front of physicians.

OptimizeRx connects pharmaceutical companies directly with physicians.